Search results
Mar 21, 2024 · CEO Mark McKenna (Mirador Therapeutics) McKenna’s new enterprise is formed around the Mirador360 platform—which he refers to as an “engine.” The technology uses data from millions of...
Aug 21, 2023 · After Mark McKenna sold a biotech for $10.8 billion, the executive recruiters likely came knocking, trying to poach the CEO who took an immunology and inflammation biotech from early-stage private financing to an IPO to key Phase II data in the span of four years.
Apr 16, 2023 · “Prometheus was established to revolutionize the treatment of immune-mediated diseases through the application of a powerful precision medicine approach,” said Mark McKenna, chairman and chief executive officer of Prometheus Biosciences.
Mar 21, 2024 · Mark McKenna is the CEO of Mirador Therapeutics, and formerly the CEO and chairman of the board at Prometheus Biosciences. Permission granted by Mirador Therapeutics. The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest venture, a biotechnology startup known as ...
- Gwendolyn Wu
Feb 5, 2024 · Mr. McKenna is the former President, Chief Executive Officer and Chairman of the Board of Directors of Prometheus Biosciences, Inc., which was acquired by Merck & Co., Inc. in June 2023 for approximately $10.8 billion.
Dec 7, 2021 · “Our design objective for PRA023 was to develop a competitive anti-TL1A antibody,” said Mark McKenna, CEO and Chairman of Prometheus Biosciences.
Dec 9, 2022 · Cramer interviewed Prometheus Biosciences CEO Mark McKenna on Friday.
- 7 min
